TNYA - Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment
- Tenaya Therapeutics ( NASDAQ: TNYA ) said the U.S. Food and Drug Administration had cleared its application to begin clinical testing of TN-301 to potentially treat heart failure with preserved ejection fraction (HFpEF).
- ( TNYA ) rose 3.1% before the bell.
- Tenaya has begun its first-in-human Phase 1 clinical trial of TN-301 in healthy adult participants.
- HFpEF is a complex disease that involves systemic inflammation, left ventricular hypertrophy, fibrosis, and diastolic dysfunction factors, and is estimated to affect more than three million people in the U.S. alone.
- In Stage 1, participants will receive single ascending doses (SAD) of either TN-301 or placebo.
For further details see:
Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment